Moderna
MRNA
195.00
-4.33
-2.17%
Moderna
US · MRNA
#406 by market cap
Listed 2018
195.00
-4.33
-2.17%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
D
Momentum strategy signal
Hold
Analyst consensus
Hold
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Improving
4 2
■ Upgrades■ Downgrades
- 4 upgrades vs 2 downgrades among tracked analyst rating changes.
- The single most recent change was actually a downgrade (William Blair moved from Buy to Hold on 2026-10-27), though the broader window skews toward upgrades.
Analyst consensus 10 analysts
Hold
Avg price target 171.63 -12.0%
Price target rangecurrent 195.00
Low80.00
Avg171.63
High305.00
Buy 20%
Hold 50%
Sell 30%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-19 | Jefferies | -- | Hold | 215.00 |
| 2026-11-16 | J.P. Morgan | -- | Sell | 102.00 |
| 2026-11-13 | Piper Sandler | -- | Buy | 305.00 |
| 2026-11-12 | BofA Securities | -- | Hold | 260.00 |
| 2026-11-12 | Citi | -- | Sell | 80.00 |
| 2026-11-09 | Piper Sandler | -- | Buy | 305.00 |
| 2026-11-09 | Citi | -- | Sell | 80.00 |
| 2026-11-06 | BofA Securities | -- | Hold | 260.00 |
| 2026-10-27 | William Blair | -- | Hold | -- |
| 2026-10-27 | BofA Securities | -- | Hold | 220.00 |
| 2026-10-27 | Citi | -- | Sell | 80.00 |
| 2026-10-26 | Piper Sandler | -- | Buy | 230.00 |
| 2026-10-26 | BofA Securities | -- | Hold | 220.00 |
| 2026-10-26 | Citi | -- | Sell | 80.00 |
| 2026-10-23 | Citi | -- | Sell | 80.00 |
| 2026-10-22 | Citi | -- | Sell | 80.00 |
| 2026-10-19 | BofA Securities | -- | Hold | 220.00 |
| 2026-10-15 | Citi | -- | Sell | 80.00 |
| 2026-10-09 | BofA Securities | -- | Hold | -- |
| 2026-10-01 | Citi | -- | Sell | 80.00 |
| 2026-09-28 | J.P. Morgan | -- | Sell | -- |
| 2026-09-18 | BofA Securities | -- | Hold | 170.00 |
| 2026-09-11 | DBS | -- | Hold | 150.00 |
| 2026-09-03 | Rothschild & Co Redburn | -- | Sell | 81.00 |
| 2026-08-27 | Argus Research | -- | Buy | 180.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-27 | William Blair | Buy → Hold | -- |
| 2026-10-01 | Citi | Hold → Sell | 80.00 |
| 2026-08-27 | Argus Research | Hold → Buy | 180.00 |
| 2026-08-25 | Wolfe Research | Sell → Hold | -- |
| 2026-08-19 | BofA Securities | Sell → Hold | 170.00 |
| 2026-08-19 | William Blair | Hold → Buy | -- |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-06 | -- | ±13.77% | +5.27% (in line) |
| 2026/Q2 | 2026-07-31 | -- | ±11.26% | -5.35% (in line) |
| 2026/Q1 | 2026-05-01 | -- | ±10.92% | -1.24% (in line) |
| 2025/Q4 | 2026-02-13 | -- | ±11.63% | +5.29% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±7.85% | +3.27% (in line) |
| 2025/Q2 | 2025-08-01 | -- | ±12.30% | -6.61% (in line) |
| 2025/Q1 | 2025-05-01 | -- | ±10.85% | -5.29% (in line) |
| 2024/Q4 | 2025-02-14 | -- | ±12.56% | +3.35% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±13.55% | -2.95% (in line) |
| 2024/Q2 | 2024-08-01 | -- | ±8.25% | -21.01% (beat) |
| 2024/Q1 | 2024-05-02 | -- | ±7.67% | +12.68% (beat) |
| 2023/Q4 | 2024-02-22 | -- | ±9.84% | +13.53% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Moderna discussion 0 comments